Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates

J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S379-83. doi: 10.1093/infdis/jiv102. Epub 2015 May 9.

Abstract

Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.

Keywords: Ebola; adenovirus; nonhuman primates; post-exposure; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenovirus Infections, Human / immunology
  • Adenovirus Infections, Human / virology
  • Adenoviruses, Human / immunology*
  • Animals
  • Antibodies, Viral / immunology
  • Ebola Vaccines / immunology*
  • Ebolavirus / immunology*
  • Genetic Vectors / immunology*
  • Hemorrhagic Fever, Ebola / immunology*
  • Hemorrhagic Fever, Ebola / virology
  • Humans
  • Macaca fascicularis / immunology*
  • Macaca fascicularis / virology
  • Macaca mulatta / immunology*
  • Macaca mulatta / virology
  • Vaccination / methods

Substances

  • Antibodies, Viral
  • Ebola Vaccines